Test-retest reliability of a quantitative bone SPECT/CT
Not Applicable
- Conditions
- Prostate cancer
- Registration Number
- JPRN-UMIN000028645
- Lead Sponsor
- Saitama Medical University
- Brief Summary
The ICCs were 0.968 [95% CI (0.959, 0.975)] for SUVmax and 0.976 [95% CI (0.969, 0.981)] for SUVpeak. The RCs of the relative difference were 30.7% for SUVmax and 27.6% for SUVpeak, and the MAPDs of all lesions were 12.3% for SUVmax and 11.5 for SUVpeak. The RCs and the MAPDs showed comparable value with the previous report regarding repeatability studies on PET.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 13
Inclusion Criteria
Not provided
Exclusion Criteria
#1 Unable to keep supine position for 1 hour #2 Anti-cancer drug, hormone drug, radionuclide treatment or radiation therapy for bone lesion was planned during 2 bone scans #3 Person in charge considered inappropriate to include to this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method test-retest reliability
- Secondary Outcome Measures
Name Time Method